Screener
Immunovant, Inc. IMVT Other Income (Expense)
Other Income (Expense) at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Immunovant, Inc. in its filing.
Tagged under the XBRL concept us-gaap:OtherNonoperatingIncomeExpense.
The source filing: Immunovant, Inc.’s 10-K, filed May 20, 2026.
- Filed
- May 20, 2026, 7:28 AM EDT
- Fiscal year
- FY2026
- Accession
- 0001764013-26-000064
| Line item | Years Ended March 31, 2026 | Years Ended March 31, 2025 | Years Ended March 31, 2024 |
|---|---|---|---|
| General and administrative | 76,242 | 77,235 | 57,281 |
| Total operating expenses | 532,902 | 438,152 | 282,709 |
| Interest income, net | (25,330) | (24,732) | (24,948) |
| Other (income) expense, net | (2,181) | (471) | 1,008 |
| Loss before provision for income taxes | (505,391) | (412,949) | (258,769) |
| Provision for income taxes | 215 | 891 | 567 |
| Net loss | $(505,606) | $(413,840) | $(259,336) |
| Net loss per common share — basic and diluted | $(2.77) | $(2.73) | $(1.88) |
Item 8. Financial Statements and Supplementary Data
FAQ
- What is Immunovant, Inc.'s other income (expense)?
- Immunovant, Inc. (IMVT) reported other income (expense) of $798K in Q1 2026.
- How has Immunovant, Inc.'s other income (expense) changed year-over-year?
- Immunovant, Inc.'s other income (expense) decreased by 25.5% year-over-year, from $1.07M to $798K.
- What is the long-term trend for Immunovant, Inc.'s other income (expense)?
- Over 3 years (2022 to 2026), Immunovant, Inc.'s other income (expense) has grown at a 38.3% compound annual growth rate (CAGR), from -$824K to $2.18M.
- What does other income (expense) mean?
- Net total of all non-operating income and expenses not classified in specific line items — a catch-all for miscellaneous financial items.
Ask your AI about Immunovant, Inc.'s other income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude